Navigation Links
OncoGenex Announces Presentation of OGX-427 Data at the ASCO 2012 Genitourinary Cancers Symposium
Date:1/19/2012

ract #286, General Poster Session D - Feb. 3

OncoGenex will host an investigator panel to review the preliminary OGX-427 data and the on-going development program for the compound on Thursday, February 2, 2012 at 6:35 p.m. PT in San Francisco. The panel will include Prof. Joaquim Bellmunt, from the University Hospital del Mar, and Drs. Martin Gleave and Alan So, both from the University of British Columbia.

The event will also be made available via live webcast. To access the event, log on to the Investor Relations page of the OncoGenex website at www.oncogenex.com.  A replay will be made available for approximately 90 days following the event.

About OncoGenex Pharmaceuticals
OncoGenex is a biopharmaceutical company committed to the development and commercialization of new cancer therapies that address treatment resistance in cancer patients. OncoGenex has a diverse oncology pipeline, with each product candidate having a distinct mechanism of action and representing a unique opportunity for cancer drug development. OncoGenex and Teva Pharmaceutical Industries Ltd. (NASDAQ:  TEVA) have entered a global collaboration and license agreement to develop and commercialize OncoGenex' lead drug candidate, custirsen. Custirsen is currently in Phase 3 clinical development as a treatment in men with metastatic castrate-resistant prostate cancer. The companies plan to begin Phase 3 development of custirsen in first-line treatment of advanced, unresectable non-small cell lung cancer. OGX-427 is in Phase 2 clinical development; CSP-9222 and OGX-225 are currently in pre-clinical development. More information is available at www.OncoGenex.com.

OncoGenex' Forward Looking Statements

This press release contains forward-looking statements within the meaning of the "safe harbor" provisions of the Priva
'/>"/>

SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. OncoGenex Announces Publication of Phase I/II Custirsen (OGX-011/TV-1011) Data in Journal of Thoracic Oncology
2. OncoGenex Announces Completion of a Special Protocol Assessment (SPA) Amendment with the FDA Increasing Patient Eligibility for the Custirsen Phase III Prostate Cancer SATURN Clinical Trial
3. OncoGenex Pharmaceuticals, Inc. Reports Financial Results for Second Quarter 2011 and Provides Update on Development Activities
4. OncoGenex Announces Data Highlighting OGX-427 at American Association of Cancer Research (AACR) 102nd Annual Meeting 2011
5. OncoGenex Pharmaceuticals to Participate in Panel Discussion on Novel Cancer Treatments at RBC Capital Markets Healthcare Conference
6. Isis Pharmaceuticals to Receive $10 Million From OncoGenex License of OGX-011 to Teva
7. OncoGenex Expands Clinical Development of OGX-427 with a Phase 1 Clinical Trial in Bladder Cancer
8. ShangPharma Announces Milestone Achievement in Research Partnership with Hengrui
9. CME LLC Announces the Launch of the CME Activity Advances in the Management of Major Depressive Disorders
10. Neurocrine Biosciences, Inc. Announces Proposed Public Offering of Common Stock
11. Pharmaceutics International, Inc. (Pii) Announces cGMP Aseptic Facilities Expansion
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)... and Markets ( http://www.researchandmarkets.com/research/6k27gw/dental ) has announced the addition ... Analysis, Size, Share, Growth, Trends And Forecast, 2013 - ... (Logo: http://photos.prnewswire.com/prnh/20130307/600769 ) Dental ... order to treat dental impairments, for tooth restoration and ...
(Date:1/15/2014)... OAKS, Calif. , Jan. 15, 2014 ... Amgen (NASDAQ: AMGN ) announced today ... jointly discover and validate new therapeutic targets and ... a chronic disorder that affects millions worldwide. The ...
(Date:1/15/2014)... GARDENS, Fla. , Jan. 15, 2014  In an unprecedented effort ... and TB in ambulances and other transport vehicles, an advanced and ... by rescue personnel for the first time. In ... contact with these deadly pathogens, West Palm Beach ...
Breaking Medicine Technology:Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 2Dental Consumables Market - Global Industry Analysis, Size, Share, Growth, Trends And Forecast, 2013 - 2018 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 2Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 3Mass. General, Broad Institute and Amgen Will Work to Discover New Drugs for Inflammatory Bowel Disease 4Superbugs No Longer Ride In Rescue Vehicles 2
(Date:7/10/2014)... those students looking to bump up their grade point ... more time in a library or study hall, but ... shows that students who were members of the recreational ... freshman and sophomore years had higher GPAs than those ... students with memberships stayed in school longer. An increase ...
(Date:7/10/2014)... A research review identifying the clinical indicators most strongly ... the process of developing evidence-based guidelines for concussion diagnosis, ... by Neurosurgery , official journal of ... journal is published by Lippincott Williams & Wilkins ... . , Based on analysis of the best ...
(Date:7/10/2014)... just as tempting as full-fat equivalents could be ... into how proteins can replace fats without affecting ... the Engineering and Physical Sciences Research Council (EPSRC), ... of Edinburgh has produced modified proteins that easily ... the behaviour of fats during food manufacture. The ...
(Date:7/9/2014)... acute episodes of low back pain are not linked ... wind direction and precipitation. Findings published in Arthritis ... College of Rheumatology (ACR), indicate that the risk of ... or wind gusts, but was not clinically significant. ... everyone experiences low back pain at some point in ...
(Date:7/9/2014)... network of signals active in almost all types of ... overdrive, and may help fuel a tumour,s uncontrolled growth, ... Cancer Research, London, identified a molecular trigger responsible for ... the cellular factory that makes the building blocks cancer ... the TOR signalling pathway, called SREBP, controls the flow ...
Breaking Medicine News(10 mins):Health News:Want a higher GPA in college? Join a gym 2Health News:What's a concussion? Review identifies four evidence-based indicators 2Health News:What's a concussion? Review identifies four evidence-based indicators 3Health News:Great tasting low-fat cheeses and cakes could soon be on the menu 2Health News:Low back pain? Don't blame the weather 2Health News:Signal may send cancer's cellular factories into overdrive 2
... ... today announced MathMagic Personal Edition 4.8, their award-winning multi-purpose equation editor. With a ... equation editor for mathematical equations and symbols. MathMagic reads and writes various industry ... Docs and Zoho Writer, and other enhanced features. , ...
... ... and cold therapy has been cited by the American Academy of Orthopedic Surgeons as an ... selection of compressive cold therapy systems for plantar fasciitis treatment as a complement to its ... ...
... PHILADELPHIA, Dec. 3 The American Red Cross won ... Teamsters, Local 929 after its members illegally blocked vehicles ... local hospitals. , (Logo: http://www.newscom.com/cgi-bin/prnh/20081216/DC52619LOGO ) ... American Red Cross Blood Services Penn-Jersey Region earlier today. ...
... The Cancer Center at Harrington has received ... , "We expect to start seeing patients immediately," said Diane ... approval was granted today by the Massachusetts Department of Public ... , The opening of The Cancer Center at Harrington ...
... BEIJING, Dec. 3 /PRNewswire-Asia/ -- Long believed to ... important ingredients in global,cuisine, has seen increased demand in China ... timing of this ginger demand increase coincides with supply shortages,effecting ... about,a potential repeat of the current demand hysteria over garlic. ...
... SILVER SPRING, Md., Dec. 3 We are closer than ... affordable, quality care for all. The American Nurses Association ... support for meaningful health care reform. , See video from ... for a health care system that focuses on wellness and ...
Cached Medicine News:Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 2Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 3Health News:MathMagic Personal 4.8 for Windows Now Supports Google Docs and Zoho Equation 4Health News:Orthotics And Beyond Introduces Compressive Cold Therapy Products for Plantar Fasciitis Treatment 2Health News:American Red Cross Wins Court Injunction Against Striking Teamsters 2Health News:Cancer Center at Harrington to Begin Seeing Patients 2Health News:Cancer Center at Harrington to Begin Seeing Patients 3Health News:Ginger Prices Could Skyrocket on H1N1 Fears 2Health News:VIDEO from Medialink and the American Nurses Association (ANA): American Nurses Association Urges All Americans to Take Part in Health Care Reform Debate 2
The Model 5305 is a hand-held, portable, lightweight pulse oximeter designed for spot checking. It has a NiCad rechargeable battery....
The Model 340DT is a new desk top pulse oximeter that was designed for continuous pulse oximetry and has visual and audible alarms to aid with patient monitoring....
The Model 305 is a hand-held, portable, lightweight oximeter designed for spot checking. It has a NiCad rechargeable battery....
... memory capabilities for overnight sleep screening., ,The ... and pulse rate data, and can operate in ... ,1. The Model 130 can retain up ... patient, making the device ideally suited for treadmill ...
Medicine Products: